Intraperitoneal α-Emitting Radioimmunotherapy with (211)At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations

Eliminating microscopic residual disease with α-particle radiation is theoretically appealing. After extensive preclinical work with α-particle–emitting (211)At, we performed a phase I trial with intraperitoneal α-particle therapy in epithelial ovarian cancer using (211)At conjugated to MX35, the an...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Nucl Med
Hlavní autoři: Hallqvist, Andreas, Bergmark, Karin, Bäck, Tom, Andersson, Håkan, Dahm-Kähler, Pernilla, Johansson, Mia, Lindegren, Sture, Jensen, Holger, Jacobsson, Lars, Hultborn, Ragnar, Palm, Stig, Albertsson, Per
Médium: Artigo
Jazyk:Inglês
Vydáno: Society of Nuclear Medicine 2019
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6681696/
https://ncbi.nlm.nih.gov/pubmed/30683761
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.220384
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky